Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 13, 2020
Daily News
March 13, 2020
- Japan Enacts State of Emergency Bill over Coronavirus
March 13, 2020
- Japan’s Stance to Look at Overseas Examples for Copay Raises Called into Question
March 13, 2020
- Coronavirus Woes Stymie Drug Makers’ Sales Activities in Japan, Curbs on Doctor Visits Continue
March 13, 2020
- PMDA Prepares “Special Leave” System for Coronavirus Infected Staffers
March 13, 2020
- Medicago Successfully Produces COVID-19 Vaccine Candidate
March 13, 2020
- Sanofi Exploring Kevzara Use for Novel Coronavirus
March 13, 2020
- Pfizer Japan Delivers 1.1% Growth in FY2019
March 13, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…